Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics ...
Collaboration leverages Absci’s leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications VANCOUVER, ...
Results that may be inaccessible to you are currently showing.